Treatment Thresholds for Hypertension According to Canadian Guidelines
Antihypertensive therapy should be initiated at DBP ≥100 mm Hg or SBP ≥160 mm Hg in low-risk patients without target organ damage, while therapy should be strongly considered at DBP ≥90 mm Hg or SBP ≥140 mm Hg in patients with macrovascular target organ damage or cardiovascular risk factors. 1
Risk-Stratified Treatment Thresholds
The Canadian approach uses a risk-based framework that determines treatment initiation based on both blood pressure levels and cardiovascular risk profile 1:
Low-Risk Patients (No Target Organ Damage or CV Risk Factors)
- DBP threshold: ≥100 mm Hg (Grade A evidence) 1
- SBP threshold: ≥160 mm Hg (Grade A evidence) 1
- These thresholds apply when using office-based blood pressure measurement (OBPM) 1
Higher-Risk Patients (With Macrovascular Target Organ Damage or CV Risk Factors)
- DBP threshold: ≥90 mm Hg (Grade A evidence) 1
- SBP threshold: ≥140 mm Hg (Grade B evidence for 140-160 mm Hg; Grade A for >160 mm Hg) 1
- Treatment should be "strongly considered" at these lower thresholds when risk factors are present 1
High-Risk Patients Requiring Intensive Management
For patients aged ≥50 years with SBP ≥130 mm Hg who meet high-risk criteria, intensive management targeting SBP <120 mm Hg should be considered. 1
High-risk criteria include 1:
- Clinical or subclinical cardiovascular disease
- Chronic kidney disease (non-diabetic nephropathy with proteinuria <1 g/day, eGFR 20-59 mL/min/1.73 m²)
- Estimated 10-year global cardiovascular risk ≥15%
- Age ≥75 years
Updated 2025 Definition
The most recent 2025 Canadian guideline provides a uniform definition of hypertension as BP ≥130/80 mm Hg and recommends targeting systolic BP <130 mm Hg for treatment 2. This represents a shift toward lower thresholds compared to the 2020 recommendations, aligning treatment initiation more closely with the diagnostic definition.
Important Clinical Caveats
The 2020 guidelines emphasize using clinical judgment and shared decision-making when identifying treatment thresholds, considering the patient's broader clinical, social, and economic context 1. This is particularly relevant because approximately 25% of hypertensive Canadians historically fell into categories where pharmacotherapy was not recommended based on older risk-stratified approaches 3.
The guidelines distinguish between when treatment "should be prescribed" (stronger recommendation for low-risk patients at higher BP levels) versus "should be strongly considered" (for higher-risk patients at lower BP levels), reflecting the strength of evidence and clinical urgency 1.